sulfatidase; EC 3.1.6.8) activity and the lysosomal accumulation of sulfatide (galactosylceramide sulfate). 5 Inherited as an autosomal recessive condition, MLD presents in a variety of clinical forms [1] . The most common, and most severe, form of MLD is the late-infantile form, which has an onset at about age 1 year.
Juvenile
and adult-onset forms also exist. In all forms, the nervous system is affected by a progressive demyelination. Depending on the severity of the biochemical lesion, this results in developmental delays, dementia, ataxia, weakness, progressive spasticity, seizures, and (or) psychiatric abnormalities [1] .Lateonset and atypical forms of MLD have been misdiagnosed as multiple sclerosis, schizophrenia, and other conditions [1] .
The diagnosis of MLD is also complicated by the high frequency of two presumably benign alleles of the ASA gene locus, the common ASA pseudodeficiency alleles, which are associated with markedly diminished in vitro ASA activity [2, 3 ].
An estimated
10-20% of individuals in the general population are heterozygotes for the common ASA pseudodeficiency alleles [4] [5] [6] and have reduced in vitro ASA activity, similar to true heterozygotes for MLD. Likewise, individuals who are homozygous for pseudodeficiency alleles have markedly reduced in vitro ASA activity, similar to persons affected with MLD, although their in vivo sulfatidase activity is adequate to maintain sulfatide turnover and thereby prevent the development of symptoms [2, 3, 7, 8] .
Yet another complicating factor in the diagnosis of MLD is the existence of a form of MLD that is not caused by a deficiency of ASA but, rather, by a deficiency of an activator protein that works in concert with the enzyme and is required for its intracellular activity [1, 2] . Individuals with the activator deficiency form of MLD show normal in vitro amounts of ASA activity in the commonly used enzyme assays, but their in vivo activity of ASA is pathologically reduced. In such individuals, the exclusive use of leukocyte and fibroblast ASA assays would result in a false-negative result or a failure to diagnose the condition. 
SULFATIDE ANALYSIS
The complete method is outlined in Fig. 1 .
Ert-raction of glycolipids.
Aliquots of 10-20 mL of urine of known creatinine concentration were frozen at -70 #{176}C and then lyophilized in 50-mL conical plastic tubes. The residue was resuspended in 3 mL of 0.1 mol/L KCI, and transferred to 30-mL glass screw-cap tubes. After the addition of methanol (4 mL) and chloroform (8 mL), the solution was vigorously mixed at ambient temperature for at least 2 h. The resulting two phases were separated by centrifugation (400g, 10 mm), and the upper phase was discarded. The lower phase was filtered through glass wool and evaporated to dryness under nitrogen.
Alkaline hydrolysis. The samples were subjected to mild alkaline hydrolysis by the addition of I mL of 0.6 mol/L methanolic NaOH to each sample. After 1 h at ambient temperature, the reaction mixture was neutralized with 1.5 mL of 0.4 mol/L 1-ICI.
The sample was then mixed with 1 mL of methanol and 0.5 mL of water, twice passed through a 0.4-mL column of C15 silica (Sepralyte) that had been prewashed with 2.5 mL of chloroform: methanol [2:1 by vol (C:M 2:1)1, C:M (1:1), 65% ethanol, and water. The loaded column was then washed with 3.5 mL of 0.1 mol/L KCI in an equivolume mixture of methanol and water, followed by 3.5 mL of water, and the lipids were eluted from the column with 5 mL of methanol.
The sample was brought to dryness under nitrogen and redissolved in 1 mL of C:M (2:1).
Isolation of sulfatides. The sample was then applied to a 2-mL column of DEAE-52 that had been previously equilibrated with 0.8 molJL methanolic sodium acetate, washed with 8 mL of methanol, and washed with 8 mL of C:M (2:1). Residual sample was rinsed onto the column with two additional l-mL washes of C:M (2:1). Neutral lipids were eluted from the column with 15 mL of C:M (2:1), after which the sulfatide fraction was eluted with 20 mL of 0.5 mol/L potassium acetate and 0.14 mol/L ammonium hydroxide in C:M (4:1). The sulfatide fraction was brought to dryness and redissolved in 20 mL of methanol:water (1:1 by vol); the redissolved fraction was then applied twice to a 0.4-mL C15 silica column that had been equilibrated by prior washing with 2.5 mL of 0.1 mol/L KCI in an equivolume solution of methanol and water, followed by 3.5 mL of water. After the column was washed with 2.5 mL of methanol:water (1:1 by vol), the sulfatides were eluted from the column with 5 mL of methanol, and this solution was evaporated to dryness and lyophilized to remove any moisture. Hydrolysis of sulfate. The sample was subjected to mild acid hydrolysis in 1 mL of dry 0.05 mol/L methanolic HCI at ambient temperature for 16 h, after which 3 mL of chloroform, 0.5 mL of methanol, and 1.1 mL of 2 g/L sodium bicarbonate were added; the two phases were separated by centrifugation, and the upper phase was discarded. The lower phase was rinsed with 2 mL of C:M:0.l moVL aqueous KCI (3:48:47, by vol) and then with C:M:water (3 :48:47, by vol). The upper phases were discarded, and the lower phase (containing sulfatide-derived galactosylceramide) was brought to dryness and lyophilized.
Perbenzoylation. To each sample was added 0.5 mL of 100 mLIL benzoyl chloride in dry pyridine. After 16 h at 37 #{176}C, the perbenzoylated samples were brought to dryness and redissolved in 3 mL of hexane. 
Results

CHROMATOGRAPHIC RESOLUTION
Representative chromatograms are shown in Fig. 2 . These illustrate the excellent HPLC-based resolution of the sulfatide- derived hydroxy and nonhydroxy fatty acid galactosylceramides from the peaks for any other residual glycolipids.
ANALYTICAL PERFORMANCE
Linearity and dynamic range of the assay. Amounts of sulfatide ranging from 50 to 6400 pmol were added to 20 mL of water (final concentrations, 2.5-320 nmol/L) and processed as described in Materials and Methods. The assay results were linear from 100 to 6400 pmol/20 mL (Fig. 3, left) . Therefore, the limit of detection of this assay is 100 pmol of sulfatide. A similar experiment was performed by adding sulfatide standards (1000 to 11 000 pmol) to 20-mL aliquots of a normal control urine and processing as described in Materials and
Methods. As shown in Fig. 3 (right) , the assay was linear throughout this range, and calculations of the yield of sulfatide added to water vs urine were similar, indicating that there is little or no matrix effect.
Determinations
of precision. The intraassay imprecision (CV) of the urinary sulfatide assay, determined by measuring the urinary sulfatide concentrations in four aliquots of a normal control urine, was 27%. For interassay precision the urinary sulfatide concentrations were measured on 10 different occasions for one disease (MLD) control urine and on 5 different occasions for a normal control urine; the respective interassay CVs were 30% and 23%.
Determination ofyield. The yield of the sulfatide standard, 100 g in 20 mL of distilled water, was calculated with each run.
Seventeen such analyses gave a mean recovery of 29% ± 11%. [14, [18] [19] [20] . We centrifuged urine specimens from two individuals with MLD to determine whether the sulfatide was distributed principally in the pellet (i.e., the particulate fraction) or the supernate; 64% and 67% of the sulfatide was present in the particulate fraction in these two cases (Table  1) . Therefore, it is important to thoroughly mix each urine sample before taking an aliquot for analysis. 236 Natowicz et at.: Urine sulfatides and metachromatic leukodystrophy chromatography [14] . That study provided confirmation of earlier qualitative analyses [13] showing marked differences in the urinary sulfatide concentrations between normal individuals and persons with MLD. The method used was impractical for routine clinical diagnostic purposes, for it required large quantities of urine (24-h urine collections from affected individuals and 10-30 L from controls) and large SDs were noted for each group [14] . In contrast, the assay described here requires only 10-20 mL of urine and has good precision.
EVALUATION OF URINARY SEDIMENT
Nonaka and Kishimoto developed an efficient method for isolating and quantifying sulfatides from tissues by using perbenzoylation and HPLC separation [23] . However, their method was limited by high background and suboptimal resolution of sulfatides from other lipids [23] . Our method provides clear separation of sulfatides from other urinary lipids (Fig. 2) 
